PDF(Pubmed)
Abstract：
Ovarian cancer (OC) has an unfavorable prognosis. Due to the lack of effective screening tests, new diagnostic methods are being sought to detect OC earlier. The aim of this study was to evaluate the concentration and diagnostic utility of selected matrix metalloproteinases (MMPs) as OC markers in comparison with HE4, CA125 and the ROMA algorithm. The study group consisted of 120 patients with OC; the comparison group consisted of 70 patients with benign lesions and 50 healthy women. MMPs were determined via the ELISA method, HE4 and CA125 by CMIA. Patients with OC had elevated levels of MMP-3 and MMP-11, similar to HE4, CA125 and ROMA values. The highest SE, SP, NPV and PPV values were found for MMP-26, CA125 and ROMA in OC patients. Performing combined analyses of ROMA with selected MMPs increased the values of diagnostic parameters. The topmost diagnostic power of the test was obtained for MMP-26, CA125, HE4 and ROMA and performing combined analyses of MMPs and ROMA enhanced the diagnostic power of the test. The obtained results indicate that the tested MMPs do not show potential as stand-alone OC biomarkers, but can be considered as additional tests to raise the diagnostic utility of the ROMA algorithm.
摘要：
卵巢癌（OC）预后不良。由于缺乏有效的筛查测试，正在寻求新的诊断方法来更早地检测OC。这项研究的目的是与HE4，CA125和ROMA算法相比，评估选定的基质金属蛋白酶（MMPs）作为OC标记的浓度和诊断实用性。研究组由120例OC患者组成；对照组由70例良性病变患者和50例健康女性组成。通过ELISA方法测定MMPs，HE4和CA125由CMIA。OC患者的MMP-3和MMP-11水平升高，与HE4，CA125和ROMA值相似。最高的SE,SP,在OC患者中发现MMP-26，CA125和ROMA的NPV和PPV值。用选择的MMPs进行ROMA的组合分析增加了诊断参数的值。对MMP-26，CA125，HE4和ROMA获得了测试的最高诊断能力，对MMP和ROMA进行联合分析可增强测试的诊断能力。获得的结果表明，测试的MMP不显示作为独立的OC生物标志物的潜力，但可以认为是额外的测试，以提高ROMA算法的诊断效用。
